REVANESSE®

2021 **NEXT GENERATION HA** | Physician Presentation



CONTENTS

- Company Information
 - Who is Prollenium[®]?
- Story of Revanesse[®]
 - What is Revanesse[®]?
 - The unique formulation
 - Designed for safety
 - Gel particle comparison
- Science of Hyaluronic Acid (HA)
- Revanesse® Versa™ vs Nasolabial Fold (NLF) Comparator
- Revanesse® Versa™+ vs Lip Comparator
- Revanesse® Family of Products (FOP)
 - Versa[™]
- REAL PEOPLE REAL RESULTS





WHO IS PROLLENIUM®?

- Founded in 2002, Prollenium[®] is an aesthetic medical device company
- Only manufacturer of dermal fillers in North America
- Heavily invested in research and development
- Reshaping the aesthetic experience





MANUFACTURED IN CANADA


TWO STATE-OF-THE-ART MANUFACTURING FACILITIES

- Highest quality manufacturing and QA standards
- Highly regulated adhering to Good Manufacturing Practices (GMPs)
- Regulatory compliance to the highest standards (ISO 13485:2016)
- FDA approved facility





CONSISTENCY



COMPANY TIMELINE

2011 Opened the only 2002 HA dermal filler 2018 Company founded manufacturing Clinical trials facility in initiated for lip North America indication 2008

> 2017 Revanesse® Versa™ receives FDA approval

Q2020 Relocated

headquarters to 70,000 sq ft facility


Revanesse® Versa™+ (with lidocaine) receives FDA approval

2020 **•**

Revanesse[®] Lips[™]+ (with lidocaine) receives FDA approval

R&D brought

in-house



SOLD IN OVER 80 COUNTRIES WORLDWIDE

OVER 3 MILLION SYRINGES SOLD WORLDWIDE 18 YEARS OF INNOVATION






WHAT IS REVANESSE®?

- Revanesse® is a line of injectable
 Hyaluronic Acid (HA) dermal fillers that
 use state-of-the-art production
 methods, including proprietary cross linking and shaping processes that yield
 uniform, spherical particles.
- Revanesse® Versa™ is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and fold, including nasolabial folds in adults 22 years of age or older.


UNIQUE FORMULATION

- Proprietary sieving technology produces round, smooth and spherical HA particles¹
- Optimally cross-linked, long-chain, high molecular weight (25mg/mL) HA using less BDDE
- 7-Day Dialysis to neutralize pH and remove excess BDDE
- Rigorous quality control throughout manufacturing process



20X Magnification

PERCENT OF SPHERICAL PARTICLES




Test batch of Revanesse® Versa™. Graph demonstrates 68% perfectly spherical particles, where the aspect ratio of a perfect sphere is 1.0.

^{1.} BDDE Cross-linked Hyaluronan Dermal Fillers Comparison of Commercial Products Update Report RD045, 2014. Prollenium Medical Technologies Inc.

DESIGNED FOR SAFETY AND LONGEVITY

- Reduced inflammatory reaction: Inflammatory reactions are more pronounced for particles of irregular shape¹
 - Revanesse® uses only high molecular weight HA to minimize the inflammatory response for tissue integration²
 - Round and smooth HA particles that use high molecular weight HA are less likely to be recognized as foreign bodies^{1,3}
- **Durability and long-lasting:** Degree of cross-linking is optimized using Thixofix® technology.
 - Unique sieving process helps produce uniform and spherical particles
- Optimized for:
 - Elasticity (G') for lift capacity¹
 - Yield stress for shape retention¹
 - Cohesivity for tissue integration¹



20X Magnification


^{1.} Biocompatibility of Microparticles into Soft Tissue Fillers. *Semin Cutan Med Surg.* 2004; 23(4): 214-217.

^{2.} Testing from Prollenium Medical Technologies Inc. Data on file.

High and Low Molecular Weight Hyaluronic Acid Differentially Influence Macrophage Activation. ACS Biomater Sci Eng. 2015; 1(7): 481-493.




PRODUCT SYNTHESIS FLOW CHART



MODIFICATION

THE EFFECT OF MODIFICATION IS TO INCREASE DURABILITY (STABILITY) & LONGEVITY



Hyaluronic Acid (HA)

Natural Polysaccharide
 Ubiquitous
 15 g / person

Testing from Prollenium Medical Technologies Inc. Data of file.

For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

Modification helps promote cross-links between different HA polymer chains.

Excessive cross-linking can create hard implants and increase the safety risk or incidence of adverse reactions (AEs).

Optimized modification is important for balancing safety and durability.

MOLECULAR WEIGHT

REVANESSE® EXCLUSIVELY USES HIGH MOLECULAR WEIGHT HYALURONIC ACID WHICH REQUIRES LESS BDDE TO MAKE EFFECTIVE LINKS



Less BDDE is required to link higher molecular weight HA

Reduces incidence of inflammatory response


Shorter HA chains have lower molecular weight and require more BDDE to achieve effective links

- Low and medium molecular weight HA may potentially increase inflammatory responses
- Using more BDDE theoretically makes modified HA less natural and more likely to produce adverse reactions

High and Low Molecular Weight Hyaluronic Acid Differentially Influence Macrophage Activation. *ACS Biomater Sci Eng.* 2015; 1(7): 481-493.

OPTIMIZATION


REVANESSE USES THIXOFIX® TECHNOLOGY TO OPTIMALLY CROSS-LINK HIGH MOLECULAR WEIGHT HA



Using proprietary Thixofix® cross-linking technology, Revanesse® Versa™ has a balance between safety and duration

ELASTICITY (G')

G' IS THE MEASURE OF ELASTICITY AND CALLED THE ELASTIC MODULUS



Rheometer




Jello-Like (Elastic)

Measured via a rheometer

G' establishes the elastic behavior (stiffness or lift capacity) of an HA gel or its ability to recover its shape after shear deformation (injection process)

G' ELASTIC MODULUS (1HZ)

G' IS THE MEASURE OF ELASTICITY AND CALLED THE ELASTIC MODULUS



BDDE Cross-linked Hyaluronan Dermal Fillers Comparison of Commercial Products Update Report RD045 For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

VISCOSITY

VISCOSITY IS A MEASURE OF RESISTANCE TO FLOW (THICKNESS) WHEN SHEAR DEFORMATION IS APPLIED DURING THE INJECTION PROCESS




Honey-Like (Flow)

Viscosity measures how liquid the product is for creating volume

Basics of Dermal Filler Rheology. $Dermatol\ Surg.\ 2015;\ 41:\ S120-S126.$ For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

G" VISCOUS MODULUS (0.7HZ)


VISCOSITY IS A MEASURE OF RESISTANCE TO FLOW (THICKNESS) WHEN SHEAR DEFORMATION IS APPLIED DURING THE INJECTION PROCESS



M.H. Gold, Stafford Baumann, C.P. Clark III, J. Schlessinger

VISCOELASTICITY

REVANESSE® PRODUCTS OFFER THE NECESSARY VISCOELASTICITY



For smooth extrusion during injections

Ideal mechanical properties after injections

For treating different injectable depths

For adapting to dynamic facial forces


Testing from Prollenium Medical Technologies Inc. Data of file.

For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

REVANESSE®

YIELD STRESS

YIELD STRESS IS A MEASURE OF THE AMOUNT OF FORCE REQUIRED TO DEFORM THE HA GEL



Shape Retention


Provides insight into how well an HA gel deposit retains its initial shape after implantation

Testing from Prollenium Medical Technologies Inc. Data of file.

For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

G" VISCOUS MODULUS (0.7HZ)

VISCOSITY IS A MEASURE OF RESISTANCE TO FLOW (THICKNESS) WHEN SHEAR DEFORMATION IS APPLIED DURING THE INJECTION PROCESS




BDDE Cross-linked Hyaluronan Dermal Fillers Comparison of Commercial Products Update Report RD045 For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

PRODUCT OVERVIEW

Test	Versa™	Benefit
Needle (G)	27	Size of the needle bore for determining how much product is extruded
Degree of Modification – % modified w/ BDDE	6.9%	Higher amount increases stability for durability and longevity
Mean Extrusion Force (LBS)	2.4	Provides injection control for accuracy and precision
G' (Pa @ 1.0Hz)	110	Creates stiffness (lift capacity); measures how <u>solid</u> it is
Degradation Rate (Pa/H)	2.2	Duration and safety; higher number results in faster absorption
Viscosity (Pa.S) – <u>not</u> G"	2500	Assists in creating volume; measures how <u>liquid</u> it is
Swell Ratio (SwF) – To Reach Equilibrium	3.7X	Low water absorption after implantation
Cohesivity (mg/drop) – Drop Weight Method	26	How well the gel resists dynamic facial forces after implantation; higher value provides more resistance
Yield Stress (Pa) - Shape Retention	23.6	How the product retains its shape; how much force is required to deform the gel

Testing from Prollenium Medical Technologies Inc. Data of file.



STUDY DESIGN

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, SPLIT-FACE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF REVANESSE® VERSA™ VS COMPARATOR FOR THE CORRECTION OF NASOLABIAL FOLDS

- Qualified subjects had Nasolabial Folds (NLFs) with a Wrinkle Severity Rating Scale (WSRS) score of 3 or 4 (moderate or severe)
- Side by side comparison: NLFs treated with Revanesse[®] Versa[™] on one side of the face and Comparator on the other side of the face
- Side of the face for each product was randomly assigned
- Evaluating investigator and subject were blinded and injections were performed by unblinded physician
- Maximum of 2mL per fold
- All initial treatments were administered at baseline and in addition to WSRS, evaluations


- included the Global Aesthetic Improvement scale (GAI) of the investigator and the patients, as well as adverse events recorded in a diary of each subject
- Based on use of photographs, the WSRS is designed to quantify facial folds by visual assessment of the length and apparent depth of the fold without referring to baseline
- In contrast, the GAI scale is used to grade overall improvement in each fold by comparing its appearance at follow up against a high magnification photograph taken before treatment
- For subjects not requiring retreatment, the study period ended at Visit 6 / Week 24

Revanesse® Versa™ Clinical Study Report SYM 2014-02: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Versa™ ersus Restylane® for the Correction of Nasolabial Folds. Revanesse® Versa™ is a registered trademark of Prollenium Medical Technologies Inc. Restylane® is a registered trademark of Nestlé Skin Health S.A.

For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

1° EFFICACY


MEAN WRINKLE SEVERITY RATING SCALE (WSRS)



Revanesse® Versa™ Clinical Study Report SYM 2014-02: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Versa™ versus Restylane® for the Correction of Nasolabial Folds. Revanesse® Versa™ is a registered trademark of Prollenium Medical Technologies Inc. Restylane® is a registered trademark of Nestlé Skin Health S.A.

2° EFFICACY


PERCENT AT VISIT 6 / WEEK 24 (PER-PROTOCOL)



- 1 At least a 1-grade improvement in WSRS score from baseline
- 2 Categories of "much improved" or "very much improved"

Revanesse® Versa™ Clinical Study Report SYM 2014-02: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Versa™ versus Restylane® for the Correction of Nasolabial Folds. Revanesse® Versa™ is a registered trademark of Prollenium Medical Technologies Inc. Restylane® is a registered trademark of Nestlé Skin Health S.A. For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

PAIN AT INJECTION SITE




66.3% of the ITT subjects treated with Comparator reported pain at the injection site vs. 38.0% of the subjects treated with Versa™

Revanesse® Versa™ Clinical Study Report SYM 2014-02: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Versa™ versus Restylane® for the Correction of Nasolabial Folds. Revanesse® Versa™ is a registered trademark of Prollenium Medical Technologies Inc. Restylane® is a registered trademark of Nestlé Skin Health S.A.

For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

ITT: Intent-to-Treat subjects

SWELLING AT INJECTION SITE




71.2% of the ITT subjects treated with Comparator reported swelling at the injection site vs. 47.2% of the subjects treated with Versa™

Revanesse® Versa™ Clinical Study Report SYM 2014-02: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Versa™ versus Restylane® for the Correction of Nasolabial Folds. Revanesse® Versa™ is a registered trademark of Prollenium Medical Technologies Inc. Restylane® is a registered trademark of Nestlé Skin Health S.A.

For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

ITT: Intent-to-Treat subjects

SEVERE TEAEs AT INJECTION SITE




7.4% of the ITT subjects treated with Comparator reported severe TEAEs at the injection site vs. 0.6% of the subjects treated with Versa™

Revanesse® Versa™ Clinical Study Report SYM 2014-02: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Versa™ versus Restylane® for the Correction of Nasolabial Folds. Revanesse® Versa™ is a registered trademark of Prollenium Medical Technologies Inc. Restylane® is a registered trademark of Nestlé Skin Health S.A. For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

ITT: Intent To Treat subjects

SUMMARY OF INJECTION SITE TEAEs



84.0% of the ITT subjects treated with Comparator reported TEAEs vs. 69.9% of the subjects treated with Versa[™]

Revanesse® Versa™ Clinical Study Report SYM 2014-02: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Versa™ versus Restylane® for the Correction of Nasolabial Folds. Revanesse® Versa™ is a registered trademark of Prollenium Medical Technologies Inc. Restylane® is a registered trademark of Nestlé Skin Health S.A.

For more information on Revanesse® and Important Safety Information, please visit RevanesseUSA.com

ITT: Intent To Treat subjects

CLINICAL TRIALS HIGHLIGHTS

REVANESSE® VERSA™ HAS BEEN PART OF THREE CLINICAL TRIALS, INVOLVING MORE THAN 300 PATIENTS.

- Multicenter Double-Blind Randomized Split-Face Study to Evaluate Revanesse[®] Versa[™] vs. Restylane[®] for the Correction of Nasolabial Folds
- Multicenter Study to Evaluate the Safety and Efficacy of Revanesse[®] Versa[™] Retreatment
- Study to Evaluate the Safety and Efficacy of Revanesse[®] Versa[™] + vs. Revanesse[®] Versa[™] for the Correction of Nasolabial Folds


STUDIES DEMONSTRATE

- Over 300 subjects treated with no serious adverse events reports
- Non-inferiority to Restylane
- Less swelling
- 1-year pGAI data with optimal correction (subjects did not go back to baseline)



REAL PEOPLE REAL RESULTS

BEFORE & AFTER







🌞 Made in Canada

REAL PEOPLE REAL RESULTS

BEFORE & AFTER





🌞 Made in Canado

REAL PEOPLE REAL RESULTS

BEFORE & AFTER





REAL PEOPLE REAL RESULTS

BEFORE & AFTER





Made in Canado

REAL PEOPLE REAL RESULTS

BEFORE & AFTER

Nasolabial folds treated with Versa[™]. Results may vary for other patients.





BEFORE AFTER

Made in Canado

REAL PEOPLE REAL RESULTS

BEFORE & AFTER

Nasolabial folds treated with Versa[™]. Results may vary for other patients.





BEFORE AFTER

Made in Canado

REAL PEOPLE REAL RESULTS

BEFORE & AFTER

Nasolabial folds treated with Versa[™]. Results may vary for other patients.





BEFORE AFTER



9121 Anson Way, Suite 200 Raleigh, NC 27615

Phone: (866) 353-3015

info@prolleniumus.com

RevanesseUSA.com









DEGREDATION TESTING

